{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:22:39Z","timestamp":1781191359111,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Short-acting progestin-only injectables containing depot medroxyprogesterone acetate (DMPA) are a safe method of contraception. Although DMPA has been available for several decades, there is little data on its influence on the risk of breast cancer. Hence, the aim of this paper was to provide an overview of the existing studies and create clarity regarding a possible association with breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Literature searches were executed in MEDLINE, Embase, the Cochrane Library, ClinicalTrials.gov and ICTRP. Search terms were related to DMPA and breast cancer. After elimination of duplicates, 3\u2032850 studies were identified and assessed according to inclusion and exclusion criteria. Finally, ten studies were selected and included in this review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All the selected papers were case\u2013control-studies, except for one pooled analysis and one study comparing observed and expected number of cancer cases.<\/jats:p>\n                <jats:p>Most of the included studies found no overall elevated breast cancer incidence in DMPA users, only one study found a slightly increased risk and two studies concluded with a significant increase for the overall breast cancer risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There is little evidence that DMPA may increase the overall risk for breast cancer. However, the incidence of breast cancer is possibly increased in current and more recent users, especially in women younger than 35\u00a0years. Long-term use did not result in any risk increase. Nevertheless, further studies will be necessary to confirm these findings and weigh up the individual risks and benefits of this contraceptive method.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-023-07265-5","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T10:02:13Z","timestamp":1700042533000},"page":"1175-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Depot medroxyprogesterone acetate and breast cancer: a systematic review"],"prefix":"10.1007","volume":"309","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-2125","authenticated-orcid":false,"given":"Aline","family":"Z\u00fcrcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Knabben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-5226","authenticated-orcid":false,"given":"Marc","family":"von Gernler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-1552","authenticated-orcid":false,"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"7265_CR1","unstructured":"United Nations, United Nations, Department of Economic and Social Affairs, Population Division (2019) Contraceptive Use by Method 2019: Data Booklet."},{"key":"7265_CR2","volume-title":"A clinical guide for contraception","author":"L Speroff","year":"1992","unstructured":"Speroff L, Darney PD (1992) A clinical guide for contraception. Williams & Wilkins, Philadelphia"},{"issue":"2","key":"7265_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/1054-139X(95)00322-J","volume":"19","author":"Z Harel","year":"1996","unstructured":"Harel Z et al (1996) Adolescents\u2019 reasons for and experience after discontinuation of the long-acting contraceptives depo-provera and norplant. J Adolesc Health 19(2):118\u2013123. https:\/\/doi.org\/10.1016\/1054-139X(95)00322-J","journal-title":"J Adolesc Health"},{"issue":"4","key":"7265_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM et al (2016) The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 27(4):1281\u20131386. https:\/\/doi.org\/10.1007\/s00198-015-3440-3","journal-title":"Osteoporos Int"},{"issue":"3","key":"7265_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"7265_CR6","doi-asserted-by":"publisher","unstructured":"von Gernler M, Z\u00fcrcher A, Stute P (2022) Influence of depot medroxyprogesterone acetate on the risk of breast cancer [MEDLINE]. searchRxiv. https:\/\/doi.org\/10.1079\/searchRxiv.2022.00050","DOI":"10.1079\/searchRxiv.2022.00050"},{"key":"7265_CR7","doi-asserted-by":"publisher","unstructured":"von Gernler M, Z\u00fcrcher A, Stute P (2022) Influence of depot medroxyprogesterone acetate on the risk of breast cancer [Ovid Embase]. searchRxiv. https:\/\/doi.org\/10.1079\/searchRxiv.2022.00063","DOI":"10.1079\/searchRxiv.2022.00063"},{"key":"7265_CR8","doi-asserted-by":"publisher","unstructured":"von Gernler M, Z\u00fcrcher A, Stute P (2022) Influence of depot medroxyprogesterone acetate on the risk of breast cancer [ICTRP]. searchRxiv. https:\/\/doi.org\/10.1079\/searchRxiv.2022.00061","DOI":"10.1079\/searchRxiv.2022.00061"},{"key":"7265_CR9","doi-asserted-by":"publisher","unstructured":"von Gernler M, Z\u00fcrcher A, Stute P (2022) Influence of depot medroxyprogesterone acetate on the risk of breast cancer [Cochrane Library]. searchRxiv. https:\/\/doi.org\/10.1079\/searchRxiv.2022.00060","DOI":"10.1079\/searchRxiv.2022.00060"},{"key":"7265_CR10","doi-asserted-by":"publisher","unstructured":"von Gernler M, Z\u00fcrcher A, Stute P (2022) Influence of depot medroxyprogesterone acetate on the risk of breast cancer [ClinicalTrials.gov]. searchRxiv. https:\/\/doi.org\/10.1079\/searchRxiv.2022.00064","DOI":"10.1079\/searchRxiv.2022.00064"},{"issue":"1","key":"7265_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13643-022-02045-9","volume":"11","author":"N Borissov","year":"2022","unstructured":"Borissov N et al (2022) Reducing systematic review burden using Deduklick: a novel, automated, reliable, and explainable deduplication algorithm to foster medical research. Syst Rev 11(1):172. https:\/\/doi.org\/10.1186\/s13643-022-02045-9","journal-title":"Syst Rev"},{"issue":"8771","key":"7265_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/0140-6736(91)91498-J","volume":"338","author":"WHO Collaborative Study of Neoplasia and Steroid Contraceptives","year":"1991","unstructured":"WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991) Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 338(8771):833\u2013838. https:\/\/doi.org\/10.1016\/0140-6736(91)91498-J","journal-title":"Lancet"},{"issue":"6","key":"7265_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/0010-7824(80)90029-3","volume":"21","author":"AR Greenspan","year":"1980","unstructured":"Greenspan AR et al (1980) The association of depo-medroxyprogesterone acetate and breast cancer. Contraception 21(6):563\u2013569. https:\/\/doi.org\/10.1016\/0010-7824(80)90029-3","journal-title":"Contraception"},{"issue":"6","key":"7265_CR14","first-page":"1247","volume":"79","author":"NC Lee","year":"1987","unstructured":"Lee NC et al (1987) A case\u2013control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 79(6):1247\u20131254","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"7265_CR15","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1158\/0008-5472.can-11-4064","volume":"72","author":"CI Li","year":"2012","unstructured":"Li CI et al (2012) Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Can Res 72(8):2028\u20132035. https:\/\/doi.org\/10.1158\/0008-5472.can-11-4064","journal-title":"Can Res"},{"issue":"6702","key":"7265_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/bmj.299.6702.759","volume":"299","author":"C Paul","year":"1989","unstructured":"Paul C, Skegg DC, Spears GF (1989) Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. BMJ 299(6702):759\u2013762. https:\/\/doi.org\/10.1136\/bmj.299.6702.759","journal-title":"BMJ"},{"issue":"4","key":"7265_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/oxfordjournals.aje.a010219","volume":"151","author":"S Shapiro","year":"2000","unstructured":"Shapiro S et al (2000) Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen\/progestogen contraceptives. Am J Epidemiol 151(4):396\u2013403. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a010219","journal-title":"Am J Epidemiol"},{"issue":"5","key":"7265_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.contraception.2003.12.015","volume":"69","author":"BL Strom","year":"2004","unstructured":"Strom BL et al (2004) Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69(5):353\u2013360. https:\/\/doi.org\/10.1016\/j.contraception.2003.12.015","journal-title":"Contraception"},{"issue":"3","key":"7265_CR19","doi-asserted-by":"publisher","first-page":"e1001182","DOI":"10.1371\/journal.pmed.1001182","volume":"9","author":"M Urban","year":"2012","unstructured":"Urban M et al (2012) Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black south African women: case\u2013control study. PLoS Med 9(3):e1001182. https:\/\/doi.org\/10.1371\/journal.pmed.1001182","journal-title":"PLoS Med"},{"issue":"10","key":"7265_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.273.10.799","volume":"273","author":"DC Skegg","year":"1995","unstructured":"Skegg DC et al (1995) Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 273(10):799\u2013804. https:\/\/doi.org\/10.1001\/jama.273.10.799","journal-title":"JAMA"},{"issue":"21","key":"7265_CR21","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1001\/jama.1983.03330450039022","volume":"249","author":"AP Liang","year":"1983","unstructured":"Liang AP et al (1983) Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 249(21):2909\u20132912","journal-title":"JAMA"},{"issue":"5","key":"7265_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.bjc.6603618","volume":"96","author":"A Fabre","year":"2007","unstructured":"Fabre A et al (2007) Oral progestagens before menopause and breast cancer risk. Br J Cancer 96(5):841\u2013844. https:\/\/doi.org\/10.1038\/sj.bjc.6603618","journal-title":"Br J Cancer"},{"issue":"11","key":"7265_CR23","first-page":"1375","volume":"11","author":"M Kumle","year":"2002","unstructured":"Kumle M et al (2002) Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women\u2019s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomark Prev 11(11):1375\u20131381","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"7265_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/bf00051883","volume":"7","author":"DC Skegg","year":"1996","unstructured":"Skegg DC et al (1996) Progestogen-only oral contraceptives and risk of breast cancer in New Zealand. Cancer Causes Control 7(5):513\u2013519. https:\/\/doi.org\/10.1007\/bf00051883","journal-title":"Cancer Causes Control"},{"issue":"10204","key":"7265_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s0140-6736(19)31709-x","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159\u20131168. https:\/\/doi.org\/10.1016\/s0140-6736(19)31709-x","journal-title":"Lancet"},{"issue":"4","key":"7265_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT et al (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA 324(4):369\u2013380. https:\/\/doi.org\/10.1001\/jama.2020.9482","journal-title":"JAMA"},{"issue":"4","key":"7265_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/gme.0000000000002154","volume":"30","author":"RT Chlebowski","year":"2023","unstructured":"Chlebowski RT, Aragaki AK (2023) The Women\u2019s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause 30(4):454\u2013461. https:\/\/doi.org\/10.1097\/gme.0000000000002154","journal-title":"Menopause"},{"issue":"6","key":"7265_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00404-022-06640-y","volume":"307","author":"A Z\u00fcrcher","year":"2023","unstructured":"Z\u00fcrcher A et al (2023) Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Arch Gynecol Obstet 307(6):1747\u20131761. https:\/\/doi.org\/10.1007\/s00404-022-06640-y","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"7265_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/oxfordjournals.aje.a114796","volume":"127","author":"DC Skegg","year":"1988","unstructured":"Skegg DC (1988) Potential for bias in case\u2013control studies of oral contraceptives and breast cancer. Am J Epidemiol 127(2):205\u2013212. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114796","journal-title":"Am J Epidemiol"},{"issue":"3","key":"7265_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2165\/00002018-199615030-00006","volume":"15","author":"CE Chilvers","year":"1996","unstructured":"Chilvers CE (1996) Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge. Drug Saf 15(3):212\u2013218. https:\/\/doi.org\/10.2165\/00002018-199615030-00006","journal-title":"Drug Saf"},{"issue":"1","key":"7265_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10549-015-3663-1","volume":"155","author":"M Samson","year":"2016","unstructured":"Samson M et al (2016) Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 155(1):3\u201312. https:\/\/doi.org\/10.1007\/s10549-015-3663-1","journal-title":"Breast Cancer Res Treat"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-023-07265-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-07265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T15:07:53Z","timestamp":1708787273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-023-07265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["7265"],"URL":"https:\/\/doi.org\/10.1007\/s00404-023-07265-5","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}